INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial (the “CaRe PC” trial) of INKmune™ for men with ...

Shares of INmune Bio climbed after the biotech company said its trial for treatment of a certain prostate cancer met its targets. The stock was up 11%, to $2.83, but is still down 65% over the ...

INmune Bio Inc. (NASDAQ:INMB) saw its stock jump 28% on Monday after announcing that its Phase I/II trial evaluating INKmune™ ...

Pre-earnings options volume in INmune Bio (INMB) is normal with calls leading puts 10:7. Implied volatility suggests the market is anticipating a ...

“The meaningful changes seen in a short trial are very encouraging,” said Dr. CJ Barnum, Vice President of CNS Drug Development at INmune Bio. “We are honored that Dr. Sharon Cohen will present our ...

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage ...

INmune Bio Inc. (NASDAQ: INMB) announced today that additional analyses from its Phase 2 MINDFuL trial evaluating XPro™, a ...

Inmune Bio, Inc. is a clinical stage biotechnology company, which develops immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer.

INmune Bio Contact: David Moss, CFO (858) 964-3720 [email protected] Investor Contact: Jason Nelson, Core IR (516) 842-9614 x-823 ...

BOCA RATON, FL., Nov. 14, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the ...

Investing.com -- INmune Bio Inc. (NASDAQ: INMB) stock surged 28% after the company announced its Phase I/II trial of INKmune™ in metastatic castration-resistant prostate cancer (mCRPC) met both ...